| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The molecular targets are α1A- and α1D-adrenergic receptors, with tamsulosin showing high affinity for α1A (Ki approximately 0.1 nM) and α1D subtypes and lower affinity for α1B; it competitively antagonizes norepinephrine-induced contraction of prostatic smooth muscle, reducing intraurethral pressure and improving urinary flow with fewer cardiovascular effects than nonselective α1 antagonists.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, tamsulosin-d4 HCl competes with [125I]HEAT or [3H]prazosin for recombinant human α1A and α1D receptors with Ki values in the subnanomolar to low-nanomolar range, antagonizes phenylephrine-induced contraction of isolated prostatic smooth muscle, and shows functional selectivity for α1A over α1B; the deuterated form retains α1 antagonist activity while enabling LC-MS/MS quantification. |
| ln Vivo |
In vivo, oral tamsulosin-d4 HCl reduces intraurethral pressure and improves urinary flow in dogs and rats, lowers blood pressure to a lesser extent than nonselective α1 antagonists, and improves BPH symptoms in animal models; the labeled form is used to quantify plasma and tissue concentrations and to relate α1A/α1D occupancy to urodynamic and hemodynamic effects.
|
| Enzyme Assay |
Noncellular binding assays incubate membrane homogenates expressing recombinant human α1A, α1B, or α1D receptors with [125I]HEAT or [3H]prazosin and increasing concentrations of tamsulosin-d4 HCl; Ki values are calculated from displacement curves, and selectivity across α1 subtypes is determined.
|
| Cell Assay |
Cellular functional assays use CHO or HEK293 cells expressing α1A or α1D receptors and measure tamsulosin-d4 HCl–mediated antagonism of phenylephrine-induced calcium mobilization or inositol phosphate accumulation; antagonist potency is derived from rightward shifts of the phenylephrine concentration–response curve, with contractile responses recorded in isolated prostatic smooth muscle.
|
| Animal Protocol |
Animal protocols administer tamsulosin-d4 HCl orally to dogs or rats at doses of 0.01–1 mg/kg; intraurethral pressure, urinary flow, and blood pressure are measured, and plasma and tissue concentrations are quantified by LC-MS/MS to relate α1A/α1D occupancy to urodynamic and hemodynamic effects.
|
| References |
| Molecular Formula |
C20H25D4CLN2O5S
|
|---|---|
| Molecular Weight |
449.00
|
| CAS # |
2518100-55-3
|
| Related CAS # |
Tamsulosin hydrochloride;106463-17-6
|
| Appearance |
Typically exists as solid at room temperature
|
| SMILES |
O=S(C1=CC(C[C@H](NC([2H])([2H])C([2H])([2H])OC2=CC=CC=C2OCC)C)=CC=C1OC)(N)=O.Cl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2272 mL | 11.1359 mL | 22.2717 mL | |
| 5 mM | 0.4454 mL | 2.2272 mL | 4.4543 mL | |
| 10 mM | 0.2227 mL | 1.1136 mL | 2.2272 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.